Auspex Pharmaceuticals Company Profile (NASDAQ:ASPX)

Analyst Ratings

Consensus Ratings for Auspex Pharmaceuticals (NASDAQ:ASPX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Show:
DateFirmActionRatingPrice TargetActions
3/31/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2015Stifel NicolausDowngradeBuy -> Hold$101.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2015Robert W. BairdDowngradeOutperform -> Neutral$95.00 -> $101.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015William BlairDowngradeOutperform -> Market Perform$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015BMO Capital MarketsDowngradeOutperform -> Market Perform$105.00 -> $101.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015Piper Jaffray Cos.DowngradeOverweight -> Neutral$91.00 -> $101.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/16/2015($0.59)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.45)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014($0.33)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.39)($0.81)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auspex Pharmaceuticals (NASDAQ:ASPX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/16/2015David A StamlerInsiderSell3,000$80.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Ventures Vii Lp CmeaMajor ShareholderSell122,667$63.08$7,737,834.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Ventures Vii Lp CmeaMajor ShareholderSell84,154$61.06$5,138,443.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Ventures Vii Lp CmeaMajor ShareholderSell93,179$59.39$5,533,900.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Alex ZissonDirectorSell730,000$53.11$38,770,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015James E FlynnInsiderBuy1,500,000$56.50$84,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Panorama Capital, L.P.Major ShareholderSell270,000$53.11$14,339,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014David A StamlerInsiderSell2,660$53.55$142,443.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Ventures Vii Lp CmeaMajor ShareholderSell195,000$50.14$9,777,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014Ventures Vii Lp CmeaMajor ShareholderSell19,000$27.15$515,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2014Ventures Vii Lp CmeaMajor ShareholderSell14,500$27.02$391,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Ventures Vii Lp CmeaMajor ShareholderSell3,413$27.11$92,526.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Ventures Vii Lp CmeaMajor ShareholderSell16,500$26.97$445,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Ventures Vii Lp CmeaMajor ShareholderSell7,109$23.45$166,706.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Gerald T ProehlDirectorBuy1,466$21.75$31,885.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014Ventures Vii Lp CmeaMajor ShareholderSell25,600$23.86$610,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Ventures Vii Lp CmeaMajor ShareholderSell22,700$23.08$523,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Ventures Vii Lp CmeaMajor ShareholderSell29,600$22.03$652,088.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Ventures Vii Lp CmeaMajor ShareholderSell6,300$21.35$134,505.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Ventures Vii Lp CmeaMajor ShareholderSell1,700$20.56$34,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014R Scott GreerDirectorBuy5,190$19.25$99,907.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014James E FlynnInsiderBuy700,000$12.00$8,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Panorama Capital, L.P.Major ShareholderBuy333,334$12.00$4,000,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Pratik ShahCEOBuy8,333$12.00$99,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Sepehr SarsharDirectorBuy67,263$12.00$807,156.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Auspex Pharmaceuticals (NASDAQ:ASPX)
DateHeadline
05/31/15 10:15 PMRon Baron's Top New Stock Holdings -
05/29/15 12:23 PMDeerfield Management’s Top Health Stocks ~ Auspex Pharmaceuticals Inc (ASPX), Horizon Pharma PLC (HZNP), AbbVie Inc (ABBV) -
05/08/15 10:07 PMWhy Teva’s Specialty Medicines Performance Declined in 1Q15 -
05/05/15 03:50 PMAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquis -
05/05/15 01:03 PMTeva Completes Acquisition of Auspex Pharmaceuticals - [at noodls] - Strengthens core CNS specialty business with high promise in movement disorder treatments; expected to provide short and long-term value for Teva shareholders JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical ...
04/29/15 02:06 AMTeva 1Q15 Earnings Preview: Stock Up 10.3% since Last Quarter -
04/28/15 08:06 PMTeva Earnings Preview: Auspex Acquisition to Support Growth -
04/27/15 10:35 AMMylan rejects Teva's $40.1 billion buyout offer -
04/21/15 04:30 PMTeva offers to buy Mylan in $40.1B cash-and-stock deal -
04/20/15 07:02 AMInvesting in IPOs: Why Investors Should Proceed with Caution -
04/17/15 04:29 PMMylan skeptical of rumored Teva bid; hasn't received offer -
04/17/15 08:02 AMAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
04/02/15 10:54 AMPharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge Fund’s Cashing In On Highest Q1 Gainers -
03/31/15 09:14 AMThe Bull Case: Supply & Demand Edition -
03/30/15 06:03 PMBiz Break: Brisbane biotech bought for $1.1 billion as boom barrels on -
03/30/15 03:38 PMGLOBAL MARKETS-Stocks rally on merger activity; dollar gains -

Social

About Auspex Pharmaceuticals

Auspex Pharmaceuticals logoAuspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ASPX
  • CUSIP:
Key Metrics:
  • Previous Close: $101.00
  • 50 Day Moving Average: $94
  • 200 Day Moving Average: $59
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-4 EPS
  • Next Year EPS Consensus Estimate: $-2 EPS
Additional Links:
Auspex Pharmaceuticals (NASDAQ:ASPX) Chart for Tuesday, July, 26, 2016